

Detection of Apoptotic Tumor Response In Vivo After a Single Dose of Chemotherapy with ^{99m}Tc -Annexin V

Takafumi Mochizuki, MD¹; Yuji Kuge, PhD²; Songji Zhao, MD³; Eriko Tsukamoto, MD³; Masuo Hosokawa, MD⁴; H. William Strauss, MD⁵; Francis G. Blankenberg, MD⁶; Jonathan F. Tait, PhD⁷; and Nagara Tamaki, MD³

¹Department of Radiology, Nikko Memorial Hospital, Muroran, Japan; ²Department of Tracer Kinetics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; ³Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; ⁴Department of Pathological Oncology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; ⁵Department of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; ⁶Division of Nuclear Medicine, Department of Radiology, Stanford University School of Medicine, Stanford, California; and ⁷Department of Laboratory Medicine, University of Washington, Seattle, Washington

Annexin V, a human protein with a high affinity for phosphatidylserine, has been labeled with ^{99m}Tc to detect apoptosis in vivo. To determine the effectiveness of imaging with this agent as a reflection of the degree of apoptosis after the first dose of chemotherapy, we studied rats with an engrafted hepatoma.

Methods: Annexin V was labeled with ^{99m}Tc (specific activity, 3.0 MBq/ μg protein). Eleven days after being inoculated with allogenic hepatoma cells (KDH-8) in the left calf muscle, the rats were randomized to receive a single dose of cyclophosphamide (150 mg/kg intraperitoneally) or to serve as controls. ^{99m}Tc -annexin V was injected 20 h later. Radioactivity in tissues was determined 6 h after injection of ^{99m}Tc -annexin V. Tumor uptake of ^{14}C -iodoantipyrine was determined as a marker of tumor blood flow. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) of tissue harvested at necropsy was performed to detect apoptosis in the tumor. **Results:** Cyclophosphamide treatment significantly increased the tumor uptake (percentage activity of injected dose per gram of tissue after normalization to the animal's weight [%ID/g/kg]) of ^{99m}Tc -annexin V (0.070 ± 0.007 %ID/g/kg for treated rats and 0.046 ± 0.009 %ID/g/kg for controls, $P < 0.001$). ^{14}C -iodoantipyrine uptake was similar in the treated and untreated groups. The number of TUNEL-positive cells in the tumor was significantly larger in the treated rats (297.70 ± 50.34 cells/mm²) than in the control rats (168.45 ± 23.60 cells/mm², $P < 0.001$). Tumor uptake of ^{99m}Tc -annexin V correlated with the number of TUNEL-positive cells in the tumor ($r = 0.712$; $P < 0.001$). **Conclusion:** Tumor uptake of ^{99m}Tc -annexin V was significantly increased by a single dose of cyclophosphamide treatment, and the increase was concordant with the number of TUNEL-positive cells in the tumor. The current results are suggestive of the utility of ^{99m}Tc -annexin V as a noninvasive means to assess tumor response, although further testing, including clinical evaluation, is required.

Key Words: ^{99m}Tc -annexin V; apoptosis; tumor; chemotherapy
J Nucl Med 2003; 44:92–97

Apoptosis plays an important role in both normal physiology and many disease processes (1–5). One of the earliest events in apoptosis is the externalization of phosphatidylserine, a membrane phospholipid normally restricted to the inner leaflet of the lipid bilayer (6,7). Annexin V, a human protein with a high affinity for membrane-bound phosphatidylserine (6,8–14), has been labeled with fluorescent markers for in vitro detection of apoptotic cells (11,14) and with radioactive agents, such as ^{99m}Tc , to detect apoptosis in vivo (15–18).

In the case of tumor tissue, successful chemotherapy or radiotherapy induces apoptosis in the neoplastic cells and indicates tumor response to the therapy (15,19–24). Previous studies demonstrated that radiolabeled annexin imaging can detect apoptosis in vivo in experimental models (15–17,25–29) of tumor therapy. This experiment was performed to determine whether radiolabeled annexin imaging could identify this response after the first treatment.

MATERIALS AND METHODS

Animal Studies

All procedures involving animals were performed in accordance with the institutional guidelines of Hokkaido University (Sapporo, Japan). Male Wistar King Aptekman/Hok rats (supplied by the Experimental Animal Institute, Graduate School of Medicine, Hokkaido University) were inoculated with a suspension of KDH-8 rat hepatoma cells (1×10^6 cells per rat) into the left calf muscle (30,31).

Human annexin V was produced by expression in *Escherichia coli* as previously described (13,14,16,32–34). Annexin V was labeled with ^{99m}Tc after derivatization with hydrazinonicotinamide (specific activity, 3.0 MBq/ μg protein) (16). Eleven days after

Received Mar. 18, 2002; revision accepted Jul. 26, 2002.

For correspondence or reprints contact: Nagara Tamaki, MD, Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Kita15 Nishi7, Kita-ku, Sapporo 060-8638, Japan.

E-mail: natamaki@med.hokudai.ac.jp

intramuscular injection of KDH-8 cells, rats weighing 209–287 g were randomized to receive a single dose of cyclophosphamide (150 mg/kg intraperitoneally; $n = 9$) or to serve as controls ($n = 10$). ^{99m}Tc -annexin V (3.8 μg protein per rat) was injected intravenously 20 h later. The animals were under light ether anesthesia at the time of injection. Six hours after ^{99m}Tc -annexin V injection, the animals were sacrificed and the tumor, blood, and samples of normal tissues were removed. The tissue samples were weighed, and radioactivity was determined with a well-type scintillation counter (1480 WIZARD 3⁺; Wallac Co. Ltd., Turku, Finland). Aliquots of the tumor tissues were used to prepare formalin-fixed paraffin-embedded specimens for subsequent histologic studies. The accumulation of ^{99m}Tc -annexin V in the tissues was expressed as the percentage activity of injected dose per gram of tissue after normalization to the animal's weight (%ID/g/kg). The tumor-to-muscle ratio (T/M ratio) and the tumor-to-blood ratio (T/B ratio) were calculated from the %ID/g/kg value of each tissue.

To determine whether the chemotherapy altered tumor blood flow (which could alter delivery of radiolabeled annexin to the tumor), a separate group of tumor animals was used to assess tissue blood flow by the uptake of ^{14}C -iodoantipyrine (^{14}C -IAP) (35). Eleven days after being inoculated with KDH-8 cells, rats weighing 240–270 g were randomized to receive a single dose of cyclophosphamide (150 mg/kg intraperitoneally; $n = 4$) or to serve as controls ($n = 4$). ^{14}C -IAP (0.37 MBq per rat) purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) was intravenously injected 20 h later while the rats were under light ether anesthesia. The rats were sacrificed 40 s after injection of ^{14}C -IAP, and the tumor, blood, and samples of normal tissues were removed. The tissue samples were weighed, and radioactivity was determined with a liquid scintillation counter (1414 WinSpectral α/β ; Wallac Co. Ltd.). The accumulation of ^{14}C -IAP in the tissues was expressed as %ID/g/kg.

Detection of Apoptosis

Apoptotic nuclei were determined by direct immunoperoxidase detection of digoxigenin-labeled 3' DNA strand breaks by use of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) (36). The formalin-fixed paraffin-embedded tissues were sectioned at 3 μm and stained according to a standard procedure using a commercially available kit (apoptosis in situ detection kit Wako; Wako Pure Chemical Industries, Ltd., Tokyo, Japan). Negative and positive controls were used for the determination of TUNEL-positive cells, instead of using a reference area. The number of TUNEL-positive cells was counted on 10 randomly selected $\times 200$ fields for each section by use of a light microscope.

Statistical Analysis

All values are shown as mean \pm SD. Statistical analysis was performed using the unpaired Student t test to evaluate the significance of differences in the values between the control and treated animals. Simple regression analysis was used to compare the uptake of ^{99m}Tc -annexin V and the number of TUNEL-positive cells. A 2-tailed value of $P < 0.05$ was considered significant.

RESULTS

Biodistribution and Tumor Uptake of ^{99m}Tc -Annexin V

The tissue distribution of ^{99m}Tc -annexin V is shown in Table 1. In control rats, uptake of ^{99m}Tc -annexin V was

TABLE 1
Biodistribution of ^{99m}Tc -Annexin V

Tissue	Control ($n = 10$)	Treated ($n = 9$)	P
Blood	0.031 ± 0.004	0.033 ± 0.004	NS
Tumor	0.046 ± 0.009	0.070 ± 0.007	<0.001
Muscle	0.008 ± 0.001	0.010 ± 0.001	NS
Thymus	0.026 ± 0.004	0.061 ± 0.010	<0.001
Spleen	1.361 ± 0.204	2.331 ± 0.280	<0.01
Bone marrow	0.514 ± 0.057	1.524 ± 0.409	<0.001
Liver	0.580 ± 0.057	0.638 ± 0.062	NS
Kidney	9.501 ± 1.012	7.212 ± 0.966	NS
T/M ratio	5.60 ± 0.90	7.53 ± 1.06	<0.05
T/B ratio	1.33 ± 0.20	2.14 ± 0.31	<0.001

NS = not statistically significant.

Data are %ID/g/kg (mean \pm SD).

highest in the kidneys, followed in decreasing order by the spleen, liver, and bone marrow. Uptake of ^{99m}Tc -annexin V was significantly higher in tumor (0.046 ± 0.009 %ID/g/kg) than in muscle (0.008 ± 0.001 %ID/g/kg, $P < 0.01$) or in blood (0.031 ± 0.004 %ID/g/kg, $P < 0.05$). The T/M and T/B ratios were 5.60 ± 0.90 and 1.33 ± 0.20 , respectively.

Uptake of ^{99m}Tc -annexin V was significantly higher in treated tumors (0.070 ± 0.007 %ID/g/kg) than in control tumors (0.046 ± 0.009 %ID/g/kg, $P < 0.001$) (Table 1; Fig. 1A). Uptake in the thymus, bone marrow, and spleen was also significantly increased by cyclophosphamide treatment. In contrast, uptake in blood, muscle, the liver, and the kidneys was not significantly affected by the treatment. The T/M and T/B ratios of the treated groups were 7.53 ± 1.06 and 2.14 ± 0.31 , respectively, which were significantly higher than those of the control groups ($P < 0.05$ for T/M and $P < 0.001$ for T/B).


Biodistribution and Tumor Uptake of ^{14}C -IAP

Tissue uptake of ^{14}C -IAP is shown in Table 2. In control rats, uptake of ^{14}C -IAP was highest in the liver (0.306 ± 0.133 %ID/g/kg), followed in decreasing order by the kidneys, the bone marrow, the spleen, and muscle. Uptake of ^{14}C -IAP in tumor (0.088 ± 0.048 %ID/g/kg) was the lowest among the tissues determined. Uptake of ^{14}C -IAP in tumor was decreased by cyclophosphamide treatment (0.041 ± 0.009 %ID/g/kg, treated rats), although the difference was not significant ($P = 0.10$). Uptake of ^{14}C -IAP in other tissues did not significantly differ between the treated and control groups.

Apoptotic Cells and Relationship with ^{99m}Tc -Annexin V Uptake

TUNEL-positive cells were seen in the tumor specimens obtained from both the control rats and the treated rats (Fig. 2). The number of TUNEL-positive cells was significantly greater in the treated tumors (297.70 ± 50.34 cells/mm²) than in the control tumors (168.45 ± 23.60 cells/mm², $P <$

FIGURE 1. Uptake of ^{99m}Tc -annexin V (A) and number of TUNEL-positive cells (B) in tumor. Uptake of ^{99m}Tc -annexin V and number of TUNEL-positive cells were significantly higher in treated tumor than in control tumor. Control = control rats; treated = rats treated with cyclophosphamide (150 mg/kg intraperitoneally).



0.001) (Fig. 1B). Tumor uptake of ^{99m}Tc -annexin V correlated with the number of TUNEL-positive cells in the tissue ($r = 0.712$; $P < 0.001$) (Fig. 3).

DISCUSSION

KDH-8 tumor uptake of ^{99m}Tc -annexin V increased significantly after a single dose of cyclophosphamide chemotherapy in a rat malignant tumor model, despite a slight decrease in perfusion. The number of TUNEL-positive cells in the tumor increased after treatment and correlated with radiolabeled annexin uptake.

Chemotherapeutic drugs and irradiation induce apoptosis in both normal tissues and tumors (15,16,19–24). TUNEL staining, which marks the degraded DNA in the cell, has been used as a marker for apoptosis (36). Our results demonstrate a striking relationship between increased ^{99m}Tc -annexin V uptake and TUNEL staining after cyclophosphamide treatment. Cyclophosphamide treatment gave a 60% increase in tumor uptake of ^{99m}Tc -annexin V and a 77% increase in TUNEL-positive cells, compared with the control value. These results are similar to those previously

reported by Blankenberg et al. (16) in a model of murine B cell lymphoma.

Yang et al. (37) reported increased cellular uptake of ^{99m}Tc -annexin V after irradiation and paclitaxel treatment in an in vitro cell culture using a breast cancer cell line. They also showed increased tumor-to-nontumor ratios of ^{99m}Tc -annexin V after paclitaxel treatment by in vivo imaging experiments. Hofstra et al. (38) observed an enhanced tumor accumulation of ^{99m}Tc -annexin V in a patient with an intra-cardiac tumor.

Our results showed that ^{99m}Tc -annexin V uptake significantly correlated with the number of TUNEL-positive cells. Blankenberg et al. (16) observed annexin V accumulation in rodent heart transplants that were undergoing rejection and that occasionally had TUNEL-positive cell nuclei. In contrast, D'Arceuil et al. (29) reported a high uptake of ^{99m}Tc -annexin V in hypoxic neurons and glial cells without evidence of apoptotic nuclei by TUNEL staining in a rabbit model of neonatal hypoxic brain injury. This discrepancy appears to largely be ascribed to differences in the tissue insult of each model and the phase of apoptosis detected by annexin V and TUNEL staining (29). TUNEL staining detects DNA degradation that occurs in a late phase of apoptosis, whereas annexin V binds to the phosphatidylserine that is externalized in an earlier phase of apoptosis that immediately follows caspase-3 activation. Further studies, including those on the expression of caspase-3 messenger RNA and protein in relation to ^{99m}Tc -annexin V uptake, may be helpful to confirm the present results and provide further evidence for the potential of ^{99m}Tc -annexin V as an indicator of apoptotic tumor cells.

In addition to apoptotic cells, annexin V binds to necrotic cells, because of exposure of phosphatidylserine located in the inner leaflet of the highly permeable plasma membrane of necrotic cells (11). Annexin V localization in vivo does not appear to be entirely specific for apoptosis. The present

TABLE 2
Biodistribution of ^{14}C -IAP

Tissue	Control (n = 4)	Treated (n = 4)
Blood	0.188 ± 0.024	0.187 ± 0.027
Tumor	0.088 ± 0.048	0.041 ± 0.009
Muscle	0.111 ± 0.029	0.074 ± 0.021
Thymus	0.090 ± 0.005	0.104 ± 0.040
Spleen	0.124 ± 0.018	0.112 ± 0.051
Bone marrow	0.143 ± 0.014	0.120 ± 0.040
Liver	0.306 ± 0.133	0.246 ± 0.186
Kidney	0.237 ± 0.036	0.240 ± 0.090

Data are %ID/g/kg (mean ± SD). All values are not statistically significant.




FIGURE 2. TUNEL staining ($\times 200$) of tumor specimens in control rats (A) and treated rats (B). Cells stained brown were considered TUNEL positive. TUNEL-positive cells were observed in tumor specimens obtained from both control and treated rats.

results, however, indicate that ^{99m}Tc -annexin V accumulation can largely be ascribed to apoptotic cells in the tumor.

Accumulation of a tracer in a tissue is generally regulated by its delivery to the tissue, uptake by the tissue, and retention in the tissue. Consequently, increased blood flow may cause increased tissue accumulation of the tracer. In our study, cyclophosphamide treatment significantly increased the tumor uptake of ^{99m}Tc -annexin V. In contrast, the uptake of ^{14}C -IAP was lower in the treated rats than in the control rats, although the difference was not significant (Table 2). These results indicate that the increased accumulation of ^{99m}Tc -annexin V in the tumor is not attributable to changes in blood flow.

The present study was conducted to clarify the potential of ^{99m}Tc -annexin V to detect apoptosis early after chemo-

therapy. Thus, a relatively early time, 20 h after treatment, was selected. ^{99m}Tc -annexin V could detect the apoptotic tumor response by cyclophosphamide treatment at this time. However, experiments at various times after treatment are required to further confirm the potential of ^{99m}Tc -annexin V.

Regarding the timing after ^{99m}Tc -annexin V, Yang et al. (37) reported increased tumor-to-blood, tumor-to-lung, and tumor-to-muscle count density ratios as a function of time during their experimental period of 4 h. Our preliminary study (39) also showed that the tumor-to-blood uptake ratio of ^{99m}Tc -annexin V was significantly higher at 6 h than at 1 h. Higher ratios of tumor to blood and tumor to other tissue will contribute to the quality of images from in vivo studies, which are important in the clinical setting. In the present study, we determined the biodistribution and tumor




FIGURE 3. Correlation of uptake of ^{99m}Tc -annexin V and number of TUNEL-positive cells in tumor. Tumor uptake of ^{99m}Tc -annexin V significantly correlated with number of TUNEL-positive cells in tumor. (Uptake of ^{99m}Tc -annexin V) = $0.025 + 1.397 \times 10^{-4} \times (\text{number of TUNEL-positive cells})$; $r = 0.712$; $P < 0.001$. \circ = control rats; \square = treated rats.

uptake of ^{99m}Tc -annexin V at 6 h after injection of ^{99m}Tc -annexin V, although the optimum time after ^{99m}Tc -annexin V injection remains to be determined. Our results showed significantly higher tumor uptake of ^{99m}Tc -annexin V without significant differences in tumor weights between the control and treated animals (3.71 ± 0.56 g for treated rats and 3.62 ± 0.99 g for controls). These results suggest that ^{99m}Tc -annexin V imaging can predict treatment efficacy before tumor volumes are reduced by the treatment. However, the potential of ^{99m}Tc -annexin V for imaging apoptosis remains to be elucidated. A scintigraphic image would be helpful to demonstrate that apoptosis is visible in the image. Autoradiographic methods are also helpful for the direct comparison of tracer uptake and TUNEL-positive cells.

In our study, a relatively high dose of cyclophosphamide (150 mg/kg intraperitoneally) was used to induce apoptosis in the tumor. Blankenberg et al. (15) used a 100 mg/kg intraperitoneal dose of cyclophosphamide to induce apoptosis in murine B cell lymphoma. They also reported that ^{99m}Tc -annexin V preferentially localized to regions of intramedullary and splenic apoptotic injury induced by a 100–150 mg/kg intraperitoneal dose of cyclophosphamide—a finding that is consistent with the present results. Similar increases in tumor apoptosis and radiolabeled annexin uptake were observed by Yang et al. (37) with a 40 mg/kg intravenous dose of paclitaxel.

CONCLUSION

Tumor uptake of ^{99m}Tc -annexin V is significantly increased by cyclophosphamide treatment, and the increase was concordant with the number of TUNEL-positive cells in the tumor. The current results are suggestive of the utility of ^{99m}Tc -annexin V as a noninvasive means to assess tumor

response, although further testing, including clinical evaluation, is required.

ACKNOWLEDGMENTS

The authors are grateful to Professors Shinzo Nishi, Kazuo Miyasaka, and Toshiyuki Ohnishi of the Central Institute of Isotope Science, Hokkaido University, for supporting this work. The authors thank Koutaro Suzuki, Hidenori Katsuura, Hidehiko Omote, and Hiroshi Arai for their assistance. This work was financially supported in part by a grant from the Japanese Foundation for Multidisciplinary Treatment of Cancer.

REFERENCES

- Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer*. 1972;26:239–257.
- Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. *Cell Prolif*. 1991;24:203–214.
- Tepper CG, Studzinski GP. Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of human leukemia cell death. *J Cell Biochem*. 1993;52:352–361.
- Thompson BC. Apoptosis in the pathogenesis and treatment of disease. *Science*. 1995;267:1456–1462.
- Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. *N Engl J Med*. 1996;335:1182–1189.
- Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. *J Exp Med*. 1995;182:1597–1601.
- Fadok VA, Savill JS, Haslett C, et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. *J Immunol*. 1992;149:4029–4035.
- Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets: evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. *J Biol Chem*. 1990;265:17420–17423.
- Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. *J Biol Chem*. 1989;264:7944–7949.
- Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. *Biochem Biophys Acta*. 1994;1197:63–93.
- Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood*. 1994;84:1415–1420.
- van Heerde WL, de Groot PG, Reutelingsperger CP. The complexity of the phospholipid binding protein annexin V. *Thromb Haemost*. 1995;73:172–179.
- Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. *J Lab Clin Med*. 1994;123:741–748.
- Wood BL, Gibson DF, Tait JF. Increased phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. *Blood*. 1996;88:1873–1880.
- Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using ^{99m}Tc -radiolabeled annexin V. *J Nucl Med*. 2001;42:309–316.
- Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. *Proc Natl Acad Sci USA*. 1998;95:6349–6354.
- Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with ^{99m}Tc annexin V. *J Nucl Med*. 1999;40:184–191.
- Ohtsuki K, Akashi K, Aoki Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. *Eur J Nucl Med*. 1999;26:1251–1258.
- Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. *Ann NY Acad Sci*. 2000;926:204–216.
- Ogawa K, Shichishima T, Nakamura N, Maruyama Y. Induction of apoptosis in vivo and in vitro in hairy cell leukemia treated by deoxycoformycin. *Tohoku J Exp Med*. 2000;192:87–98.

21. Fromiguet O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. *J Bone Miner Res.* 2000;15:2211–2221.
22. Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. *Gynecol Oncol.* 2000;79:169–176.
23. Yasunaga M, Tabira Y, Okuma T, Kitamura N. Chemotherapy-induced apoptosis of lymphocytes in esophageal cancer worsens outcome. *Hepatogastroenterology.* 2000;47:1020–1025.
24. Marklund L, Henriksson R, Grankvist K. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. *Int J Cancer.* 2001;93:577–583.
25. Vriens PW, Blankenberg FG, Stoot JH, et al. The use of 99m technetium labeled annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. *J Thorac Cardiovasc Surg.* 1998;116:844–853.
26. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. *Lancet.* 2000;356:209–212.
27. Blankenberg FG, Robbins RC, Stoot JH, et al. Radionuclide imaging of acute lung transplant rejection with annexin V. *Chest.* 2000;117:834–840.
28. Ogura Y, Krams SM, Martinez OM, et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. *Radiology.* 2000;214:795–800.
29. D'Arceuil H, Rhine W, de Crespigny A, et al. ^{99m}Tc annexin V imaging of neonatal hypoxic brain injury. *Stroke.* 2000;32:2692–2700.
30. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation model. *J Nucl Med.* 2001;42:1551–1555.
31. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumors and inflammatory lesions. *Eur J Nucl Med.* 2001;28:730–735.
32. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras: construction, expression, and characterization of recombinant proteins. *J Biol Chem.* 1995;270:21594–21599.
33. Tait JF, Smith C. Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding. *Arch Biochem Biophys.* 1991;288:141–144.
34. Abrams MJ, Juweid M, tenKate CI. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. *J Nucl Med.* 1990;31:2022–2028.
35. Tatsumi M, Yutani K, Kusuoka H, Nishimura T. Technetium-99m HL91 uptake as a tumor hypoxia marker: relationship to tumor blood flow. *Eur J Nucl Med.* 1999;26:91–94.
36. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol.* 1992;119:493–501.
37. Yang DJ, Azhdarina A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using ^{99m}Tc-EC-annexin V. *Cancer Biother Radiopharm.* 2001;16:73–83.
38. Hofstra L, Dumont EA, Thimister PW, et al. In vivo detection of apoptosis in an intracardiac tumor. *JAMA.* 2001;285:1841–1842.
39. Mochizuki T, Kuge Y, Zhao S, et al. Detection of tumor response following a single dose of chemotherapy with ^{99m}Tc-annexin V [abstract]. *J Nucl Med.* 2001;42(suppl):84P.



SOCIETY OF
NUCLEAR
MEDICINE



The Journal of
NUCLEAR MEDICINE

Detection of Apoptotic Tumor Response In Vivo After a Single Dose of Chemotherapy with ^{99m}Tc -Annexin V

Takafumi Mochizuki, Yuji Kuge, Songji Zhao, Eriko Tsukamoto, Masuo Hosokawa, H. William Strauss, Francis G. Blankenberg, Jonathan F. Tait and Nagara Tamaki

J Nucl Med. 2003;44:92-97.

This article and updated information are available at:
<http://jnm.snmjournals.org/content/44/1/92>

Information about reproducing figures, tables, or other portions of this article can be found online at:
<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:
<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2003 SNMMI; all rights reserved.